Construction and in Vitro Study of Glioma-Targeted Cell Membrane Biomimetic Delivery System
HE Mei1, XU Nan1, ZHANG Shu-yue1, LI Guo-rui2, DING Xue-ying1*
1. Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China; 2. Department of Pharmacy, Changhai Hospital,Second Military Medical University,Shanghai 200082, China
Abstract：OBJECTIVE To construct a biomimetic delivery system (U251/MSN-DOX), and assess its application of glioma targeted therapy. METHODS U251 cell membrane was coated on the surface of mesoporous silica nanoparticles(MSN) by co-extrusion to prepare cell membrane biomimetic nanoparticles U251/MSN-DOX. The particle size, potential and morphology were characterized. The physical characteristics, loading content (LC) and encapsulation efficiency (EE) of these nanoparticles were determined. Their toxicity of normal cells was investigated. Their cellular uptake of different formulations in U251 was studied by flow cytometry and fluorescence confocal microscope. Additionally, we assessed the transmembrane transport efficiency of nanoparticles via in vitro BBB. RESULTS The cell membrane-coated nanoparticles U251/MSN were spherical, and a distinct "core-shell" structure could be observed. The particle size was (135.70±3.85) nm, the LC was (18.57±2.17)%, and the EE was (64.99±2.52)%. The cell experiment showed that U251/MSN had low cytotoxicity and U251/MSN-DOX exhibited stronger cellular uptake ability and BBB transporting efficiency. CONCLUSION The glioma cell membrane can be coated on the surface of MSN to construct biomimetic nanoparticles U251/MSN. The biomimetic nanoparticles not only are capable of targeting the homologous tumor cells, but also show the enhanced ability to penetrate BBB, which indicate potential applications in the field of tumor targeted drug delivery especially in brain tumor.
何美, 徐楠, 张姝月, 李国瑞, 丁雪鹰. 脑胶质瘤靶向的细胞膜仿生递药系统的构建与体外评价[J]. 中国药学杂志, 2020, 55(5): 367-374.
HE Mei, XU Nan, ZHANG Shu-yue, LI Guo-rui, DING Xue-ying. Construction and in Vitro Study of Glioma-Targeted Cell Membrane Biomimetic Delivery System. Chinese Pharmaceutical Journal, 2020, 55(5): 367-374.
RASMUSSEN B K, HANSEN S, LAURSEN R J, et al. Epidemiology of glioma:clinical characteristics, symptoms, and predictors of glioma patients grade Ⅰ-Ⅳ in the the danish neuro-oncology registry[J]. J Neuro-Oncol, 2017, 135 (3):571-579.
[2]
MADDAHI Y, ZAREINIA K, GAN L S, et al. Treatment of glioma using neuroarm surgical system[J]. Biomed Res Int, 2016:9734512.
[3]
KARIM R, PALAZZO C, EVRARD B, et al. Nanocarriers for the treatment of glioblastoma multiforme:current state-of-the-art. [J]. J Controlled Release, 2016, 227:23-37.
[4]
ZHANG H, ZHANG W, ZHOU Y, et al. Dual functional mesoporous silicon nanoparticles enhance the radiosensitivity of VPA in glioblastoma[J]. Transl Oncol, 2017, 10 (2):229-240.
[5]
ABUL B, SARWAR B, SUNIL K P, et al. Functionalized mesoporous silica nanoparticles in anticancer therapeutics[J]. Seminars Cancer Biol, 2019. Doi:10. 1016/j. semcancer. 2019. 08. 022.
[6]
BENEZRA M, PENATE-MEDINA O, ZANZONICO P B, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma[J]. J Clin Invest, 2011, 121 (7):2768-2780.
[7]
MO J, HE L, MA B, et al. Tailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood-brain barrier[J]. ACS Appl Mater Interfaces, 2016, 8 (11):6811-6825.
[8]
JIAO X X, HU C L, HE M, et al. Preparation and in vitro evaluation of angiopep-2-modifed brain-targeting polypeptide micelles [J]. Acad J Sec Mil Univ(第二军医大学学报), 2018, 39(4): 411-419.
[9]
MONACO I, CAMORANI S, COLECCHIA D, et al. Aptamer functionalization of nanosystems for glioblastoma targeting through the blood-brain barrier[J]. J Med Chem, 2017, 60 (10):4510-4516.
[10]
SU J, SUN H, MENG Q, et al. Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes[J]. Theranostics, 2017, 7 (3):523-537.
[11]
YOO J W, IRVINE D J, DISCHER D E, et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers[J]. Nat Rev Drug Dis, 2011, 10 (7):521-535.
[12]
FANG R H, JIANG Y, FANG J C, et al. Cell membrane-derived nanomaterials for biomedical applications[J]. Biomaterials, 2017, 128:69-83.
[13]
SU J, SUN H, MENG Q, et al. Long circulation red-blood-cell-mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer[J]. Adv Funct Mater, 2016, 26 (8):1243-1252.
[14]
HU C M J, FANG R H, WANG K C, et al. Nanoparticle biointerfacing by platelet membrane cloaking[J]. Nature, 2015, 526 (7571):118-121.
[15]
PARODI A, QUATTROCCHI N, VAN DE VEN A L, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions[J]. Nat Nanotechnol, 2013, 8 (1):61-68.
[16]
BOSE R J, PAULMURUGAN R, MOON J, et al. Cell membrane-coated nanocarriers:the emerging targeted delivery system for cancer theranostics[J]. Drug Dis Today, 2018, 23 (4):891-899.
[17]
KHALDOYANIDI S K, GLINSKY V V, SIKORA L, et al. MDA-MB-435 human breast carcinoma cell homo-and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions[J]. J Biol Chem, 2003, 278 (6):4127-4134.
[18]
SUN H, SU J, MENG Q, et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors[J]. Adv Mater, 2016, 28 (43):9581-9588.
[19]
LI S Y, CHENG H, QIU W X, et al. Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy[J]. Biomaterials, 2017, 142:149-161.
[20]
MAJETI R, CHAO M P, ALIZADEH A A, et al. CD47 Is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells[J]. Cell, 2009, 138 (2):286-299.
[21]
CAO H Q, DAN Z L, HE X Y, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer [J]. ACS Nano, 2016,10(8):7738-7748.
[22]
WANG L S, WU L C, LU S Y, et al. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery:improved water suspensibility and decreased nonspecific protein binding[J]. ACS Nano, 2010, 4(8):4371-4379.
[23]
BOUCHOUCHA M, C-GAUDREAULT R, FORTIN M A, et al. Mesoporous silica nanoparticles: selective surface functionalization for optimal relaxometric and drug loading performances[J]. Adv Funct Mater, 2014, 24(37):5911-5923.
[24]
LIU W, WANG F, ZHU Y, et al. Galactosylated chitosan-functionalized mesoporous silica nanoparticle loading by calcium leucovorin for colon cancer cell-targeted drug delivery[J]. Molecules, 2018, 23(12):3082.
[25]
HAN N, WANG Y, BAI J L, et al. Facile synthesis of the lipid bilayer coated mesoporous silica nanocomposites and their application in drug delivery[J]. Microporous and Mesoporous Materials, 2015, 219:209-218.
[26]
SU J H, SUN H P,MENG Q S,et al. Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes[J]. Theranostics, 2017,7(3):523-537.
[27]
SUN H P, SU J H, MENG Q S, et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors[J]. Adv Mater, 2016, 28(43):9581-9588.
2020, Vol. 55 
